Holen Sie sich die Stockscreener-App
109.03
0.59%
0.64
Vorhandelsmarkt:
103.58
-5.45
-5.00%
Schlusskurs vom Vortag:
$108.39
Offen:
$108.5
24-Stunden-Volumen:
2.70M
Relative Volume:
1.33
Marktkapitalisierung:
$21.41B
Einnahmen:
$4.81B
Nettoeinkommen (Verlust:
$1.19B
KGV:
18.29
EPS:
5.961
Netto-Cashflow:
$1.17B
1W Leistung:
+6.19%
1M Leistung:
+2.02%
6M Leistung:
+39.09%
1J Leistung:
+47.08%
1-Tages-Spanne:
$106.58
$109.48
1-Wochen-Bereich:
$100.72
$109.48
52-Wochen-Spanne:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
109.03 | 21.28B | 4.81B | 1.19B | 1.17B | 5.961 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Incyte shares fall as Q4 earnings miss overshadows revenue beat - Investing.com
Incyte earnings missed by $0.11, revenue topped estimates - Investing.com
Incyte earnings missed by $0.11, revenue topped estimates By Investing.com - Investing.com South Africa
Earnings Breakdown: Incyte Q4 - Benzinga
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
A Look Ahead: Incyte's Earnings Forecast - Benzinga
Incyte earnings up next: Can pipeline ease Jakafi reliance? - Investing.com
Incyte (INCY) Q4 Earnings: What To Expect - Finviz
Piper Sandler Raises Incyte (INCY) Price Target to $110 | INCY S - GuruFocus
Incyte sets February 10 call to unveil Q4 and full-year 2025 results - MSN
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards? - Finviz
Incyte’s Zynyz Wins CHMP Backing And Opens New EU Opportunity - simplywall.st
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - Benzinga
Incyte (INCY) Receives New "Buy" Rating and Price Target of $135 - GuruFocus
Incyte’s Transition From A Jakafi Company To A More Diversified Pharma - Citeline News & Insights
A Glimpse Into The Expert Outlook On Incyte Through 8 Analysts - Benzinga
Barclays Maintains Overweight Rating on INCY, Raises Price Targe - GuruFocus
TD Cowen Keeps Buy Rating on Incyte (INCY), Cites Roadmap to Triple Non-Jakafi Revenue by 2029 - Finviz
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
Prelude climbs as FDA clears study for Incyte-partnered cancer candidate - Seeking Alpha
FDA clears Prelude trial drug for polycythemia vera and myelofibrosis - stocktitan.net
Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY) - Finviz
Incyte (INCY) to Release Earnings on Tuesday - MarketBeat
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) - BioSpace
Value Investing Opportunity: Incyte Corp. (NASDAQ:INCY) Presents a Compelling Case - Chartmill
Incyte (INCY) Gains European Recommendation for Zynyz Therapy - GuruFocus
Incyte (INCY) Gains EMA Panel Support for Expanded Use of Zynyz - GuruFocus
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
Incyte gets positive CHMP opinion for anal cancer drug Zynyz - StreetInsider
Ruffer LLP Has $3.74 Million Holdings in Incyte Corporation $INCY - MarketBeat
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
Incyte to Report Fourth Quarter and Year-End 2025 Financial Results - Chartmill
INCY Stock Price and Chart — NASDAQ:INCY - TradingView
Here's Why Incyte (INCY) is a Strong Momentum Stock - Yahoo Finance
Incyte Corporation $INCY Stock Position Lowered by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte Corporation $INCY Stock Position Raised by Massachusetts Financial Services Co. MA - MarketBeat
Engaging In Insider Activity, Patrick Mayes At Incyte Exercises Options Worth $0 - Benzinga
Thomas Tray Decides To Exercise Options At Incyte Worth $0 - Benzinga
Engaging In Insider Activity, Matteo Trotta At Incyte Exercises Options Worth $0 - Benzinga
Breaking Update: PABLO CAGNONI Engages In Options Exercise At Incyte Realizing $0 - Benzinga
Steven Stein Decides To Exercise Options At Incyte Worth $0 - Benzinga
What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains - 富途牛牛
Reassessing Incyte (INCY) Valuation After Wells Fargo’s Neutral Downgrade - Yahoo Finance
Wells Fargo & Company Downgrades Incyte (NASDAQ:INCY) to Hold - MarketBeat
Sun Pharma settles litigation with Incyte Corp over hair loss drug Leqselvi - MSN
Incyte (INCY) Faces Downgrade and Adjusted Price Target by Wells Fargo - GuruFocus
Incyte (INCY) Faces Downgrade with Revised Price Target by Wells Fargo | INCY Stock News - GuruFocus
IBM To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
7.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):